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ABSTRACT 
Background: Various components of the coagulation cascade have been linked to breast cancer (BrCa) progression. 
In vivo results suggest that anticoagulants possess anticancer properties, but there are virtually no studies in human 
populations. Our nationwide study explored the association between anticoagulant use and BrCa survival. 
Methods: All anticoagulants used from 1995–2015 in women (n=73,170) diagnosed with invasive BrCa in Finland 
between 1995–2013 were identified from the national prescription database; women were identified from the 
Finnish Cancer Registry. Cox regressions were performed to analyze BrCa survival as a function of pre- and post-
diagnostic anticoagulant use; analyses were conducted for different anticoagulant subtypes and overall. Models 
were adjusted for age, mammography screening, tumor clinical characteristics, comorbidities, statin use, antidiabetic 
use, and antihypertensive use. To control for immortal time bias, post-diagnostic anticoagulant use was analyzed as 
a time-dependent variable. 
Results: At a median of 5.8 years after BrCa diagnosis, 10,900 (15%) women had died from BrCa. In total, 25,622 
(35%) women had used anticoagulants during the study period. Post-diagnostic anticoagulant use increased the risk 
of BrCa death (HR=1.41, 95% CI 1.33-1.49). The risk was especially high for low-molecular weight heparin, although 
the effect disappeared in long-term users. 
Conclusion: Anticoagulant use provides no clinical benefit for BrCa survival; however, the association between 
thrombosis and cancer might mask potential survival benefits. 
Impact:  Future pharmacoepidemiological studies should adjust for anticoagulant use. Research should focus on the 
use of new oral anticoagulants because these are rarely studied and might be associated with improved BrCa 
survival. 
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INTRODUCTION 
It is well known that venous thromboembolism (VTE) is more common in patients with advanced cancer [1], 
including breast cancer, and that VTE is associated with a worse prognosis [2]. In addition to their anti-clotting 
properties in vivo, anticoagulants exhibit direct antitumor properties in breast cancer cells in vitro [3-4]. 
In recent experimental studies, the expression of protease activated receptors (PARs) 1 and 2 has been associated 
with breast cancer histology and tumor size [5]. PAR1 signaling is driven by thrombin; which is not only a crucial 
element in the coagulation cascade, but it also promotes breast cancer cell growth and invasion [6-7]. The PAR2 
(coagulation factor II [thrombin] receptor-like 1) pathway, which is dependent on tissue factor, is another important 
element in the coagulation cascade and has been crucial in evoking angiogenesis during in vivo breast cancer 
experiments [8-9], possibly involving insulin-like growth factor [10]. Thus, it is tempting to speculate that 
anticoagulants may limit breast cancer growth, with this effect being mediated through the PAR signaling pathways. 
And, indeed, direct thrombin inhibitors have been shown to reduce breast cancer metastasis [11-13]. In addition, 
studies suggest that warfarin exerts anti-adhesion properties in breast cancer cells; thus, warfarin has been further 
postulated to have direct anti-metastatic properties, especially when combined with cimetidine [14]. Furthermore, 
heparins have been reported to delay tumor growth in breast cancer independent of their anticoagulant properties 
[15]. In particular, low-molecular weight heparin (LMWH) administration is associated with improved survival in 
patients with T3, T4, and M1 breast cancer [16] as classified in the international TNM classification of malignant 
tumors [TNM-classification by Union of International Cancer Control (UICC). Available at: 
https://www.uicc.org/resources/tnm]; however, the benefit for M1 patients has been challenged [17]. 
Few observational studies examine the association between breast cancer mortality and anticoagulant use. To the 
authors’ knowledge, only one previous study has been published on this topic, and it was limited to warfarin use 
[18]. That study found no risk association for pre-diagnostic warfarin use, but an increased risk of breast cancer 
death was associated with post-diagnostic warfarin use in subjects who had not previously received the drug (HR 
1.36, 95% CI 1.12-1.64). Notably, however, although the cohort included 16,523 breast cancer patients, only 400 
participants (2.4%) had used warfarin. Because experimental studies with a variety of different anticoagulant drugs 
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show promising results, and because observational studies are limited, we conducted a retrospective cohort study to 
explore the association between breast cancer survival and anticoagulant drug use in Finland between 1995–2015. 
MATERIALS AND METHODS 
Study cohort 
All diagnoses of female breast cancer in Finland between 1995–2013 were obtained from the national 
comprehensive Finnish Cancer Registry (as described in previous publications) [19-20]. Information on each patient’s 
primary therapy was also obtained from the Finnish Cancer Registry. After excluding 4,504 cases of carcinoma in situ 
with no later diagnosis of invasive carcinoma, a total of 73,170 women were left in the final cohort. 
Death-related information was obtained from the national death certificate registry of Statistics Finland, which 
assigns official causes of death based on mandatory death certificates. The available information included the death 
date and the immediate, primary, and contributory causes of death. Only deaths with breast cancer (ICD-10: C50) 
listed as the primary cause were regarded as breast cancer deaths. 
A mammography screening program was started in Finland in 1987 and became government-mandated in 1992. 
Between 1992–2009, the program had an average national coverage rate of 86.7% [20]; invitations to participate 
were sent at two-year intervals [21]. By linking our study cohort to the national Mass Screening Registry maintained 
by the Finnish Cancer Registry, we were able to obtain data on cohort members’ participation in the mammography 
screening program and the number of screening rounds attended by each. 
We obtained information on conditions that are major indications for anticoagulant use from the national Care 
Register for Health Care (HILMO), which is maintained by the National Institute for Health and Welfare; the relevant 
conditions included pulmonary embolism (ICD-10: I26.0, I26.9), venous thromboembolism (ICD-10: I82.0-82.9), and 
atrial fibrillation (ICD-10: I48). HILMO covers all public hospitals in Finland and records all diagnoses from in- and 
outpatient visits. We examined HILMO data for diagnoses made between 1995–2013. Diagnoses made during 
primary care visits are not reported in this database. Charlson comorbidity scores [22] were calculated based on 
diagnoses recorded in the HILMO database during the follow-up timeframe. 
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Information on anticoagulant usage 
In order to obtain information on anticoagulant use, the study cohort was linked to the national medication 
reimbursement database maintained by the Social Insurance Institution (SII) of Finland. As a part of the national 
health insurance program that covers all Finnish citizens, SII provides reimbursement for physician-prescribed drugs 
[23]. In Finland, all citizens of every age are eligible for medication reimbursements. The Government-directed 
Pharmaceutical Pricing Board (HILA) decides which medications are eligible for reimbursement; most physician-
prescribed drugs used for the treatment of disease are covered. During the study period, drug reimbursements 
ranged from 35% to 100%, depending on condition severity [Finnish Statistics on Medicines. Available at: 
https://www.kela.fi/documents/10180/1889281/SLT+2013_net.pdf/0758ba68-1886-4b69-bdb6-b7566e9daa2c]. 
The reimbursement system began in 1970 [History of Medication reimbursements in Finland. Available at: 
https://www.kela.fi/web/en/operations-history]. The study cohort was linked to the reimbursement database using 
the unique personal identity code assigned to all residents of Finland. All anticoagulant drugs are physician-
prescribed in Finland; thus, all reimbursements in outpatient settings are recorded in the database However, drugs 
used during inpatient hospital visits are not recorded in the database. 
All 14 anticoagulant drugs used in an outpatient setting during 1995–2015 were identified based on their 
Anatomical-Therapeutic-Chemical codes. The identified drugs included two vitamin K antagonists (warfarin 
[B01AA03] and phenindione [B01AA02]), three heparins (dalteparin [B01AB04], enoxaparin [B01AB06], and 
tinzaparin [B01AB10]), four platelet aggregation inhibitors (clopidogrel [B01AC04], dipyridamole [B01AC30], iloprost 
[B01AC11], and ticlopidine [B01AC05]), two direct thrombin inhibitors (dabigatran [B01AE07] and ximelagatran 
[B01AE05]), and three factor Xa inhibitors (rivaroxaban [B01AX06], apixaban [B01AF02], and fondaparinux 
[B01AX05]). We also obtained information on the use of cholesterol-lowering drugs, antihypertensive drugs, and 
antidiabetic drugs (Supplementary Table 1) that may influence breast cancer survival [24-26]. 
Statistical analysis 
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Cox proportional hazard regressions were used to calculate hazard ratios (HR) and 95% confidence intervals (CI) for 
breast cancer death. The follow-up timeframe started at breast cancer diagnosis and continued until death, 
emigration, or January 1, 2016 (whichever came first). 
During analysis, we used two different model adjustments. First, the Cox regression model was adjusted for age only. 
Then, the Cox regression model was adjusted for age, breast cancer spreading at diagnosis (localized, locally 
advanced, or metastatic; information available for 85.6% of cases), primary treatment (available for 99.6% of cases), 
Charlson comorbidity score, number of mammography screening rounds attended, diabetes diagnosis, 
antihypertensive drug use, statin use, hormonal treatment, tumor histology (ductal invasive, lobular invasive, or 
other invasive; available for 99.9% of cases), and indications for anticoagulant use. 
We performed four separate analyses related to the pre- and post-diagnostic use of anticoagulants: 1) users of any 
anticoagulant drug compared to nonusers; 2) warfarin users compared to anticoagulant nonusers; 3) LMWH users 
compared to anticoagulant nonusers; 4) warfarin users compared to users of other anticoagulants. 
We calculated each woman’s total annual anticoagulant use; this amount was calculated for each calendar year and 
separately for the pre- and post-diagnostic periods. Doses between different anticoagulants were standardized by 
dividing the annual total milligram amount by the standard defined daily dose (DDD) listed by the World Health 
Organization [WHO ATC/DDD index 2016. Available at: http://www.whocc.no/atc_ddd_index/]. Each year with a 
registered anticoagulant purchase was considered a year of usage, regardless of the purchase amount. The intensity 
of a woman’s anticoagulant use was estimated by dividing the sum of all her annual doses by the number of years 
she used anticoagulants. 
Pre-diagnostic anticoagulant use was analyzed as a time-fixed variable. Cumulative use from 1995 onward was 
stratified by tertiles. Post-diagnostic use was analyzed as a time-dependent variable. Both user status and 
cumulative use were updated separately for each year of follow-up, beginning from the year of breast cancer 
diagnosis. Women were categorized as nonusers until their first recorded anticoagulant purchase; they maintained 
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their user status for each year with recorded anticoagulant purchases. Women who discontinued anticoagulant use 
were categorized as previous users. Women remained categorized as previous users unless anticoagulant use was 
restarted at another point during the follow-up timeframe; their status was then changed back to current user. User 
status was updated annually. Similarly, cumulative amount, use duration, and average annual dose were updated for 
each follow-up year. In the main analysis, we included user status and cumulative duration of use. Cumulative 
amounts and usage intensities were included in additional analyses. 
In the analysis comparing warfarin users to anticoagulant nonusers, women were categorized as warfarin users each 
year with recorded purchases of warfarin, even if other anticoagulants were also used during that year. A similar 
methodology was used to compare LMWH users to anticoagulant nonusers. In the analysis comparing warfarin users 
to users of other anticoagulants, women were considered users of other anticoagulant drugs if they had recorded 
purchases of an anticoagulant other than warfarin. 
The long-term impact of post-diagnostic anticoagulant use was assessed in a lag-time analysis. More specifically, 
anticoagulant exposure was lagged 1 to 3 years forward from the actual year of usage (i.e., its effect was ignored for 
the first 1 to 3 years following initial exposure). This approach is crucial because anticoagulants are used to treat 
breast cancer symptoms, and thus anticoagulant use may be associated with an elevated risk of breast cancer death 
in the short term. This phenomenon is known as protopathic bias [27]. 
We performed subgroup analyses for post-diagnostic anticoagulant use stratified by clinical and background 
characteristics. In the subgroup analyses, Charlson comorbidity scores were stratified into 3 groups (0 points, 1 
point, and 2 or more points). We tested the statistical significance of each background variable’s effect modification; 
this was done by adding an interaction term between anticoagulant use and the tested background variable to the 
Cox regression analysis and determining whether or not inclusion of the interaction term improved model fit. A P 
value <0.05 was considered statistically significant. 
To evaluate the impact of advanced disease on breast cancer survival, we performed a sensitivity analysis in which 
patients with metastases or unknown spreading at diagnosis were excluded. The role that the timing of breast 
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cancer diagnosis plays in survival was determined by including diagnosis year in the Cox regression model during 
sensitivity analysis. 
For 5,412 women in the Tampere University Hospital area, we also obtained information on hormone receptor 
status (estrogen receptor [ER] and progesterone receptor [PR]) and HER2 (human epidermal growth factor receptor 
2) receptor status during a woman’s first breast cancer diagnosis between 1995–2013. Adjusting for the same
control variables included in the main analysis, we conducted multivariate analyses relating anticoagulant use, 
warfarin use, and LMWH use to breast cancer survival; this allowed us to evaluate the prognostic value of these 
factors. 
All statistical analyses were carried out using IBM SPSS Statistics 22.0. All statistical tests were two-sided. 
RESULTS 
Population characteristics 
At a median follow-up of 5.8 years after breast cancer diagnosis, a total of 22,520 (31%) women had died; for 10,900 
(15%) of those women, breast cancer was the primary cause of death. A total of 25,622 (35%) women had used 
anticoagulants between 1995–2015. Of those women, 10,594 (41%) had used warfarin, and 14,224 (56%) had been 
prescribed LMWH. Compared to nonusers, women who used anticoagulants were older at breast cancer diagnosis 
(median age 66 and 59 years, respectively). The median age at breast cancer diagnosis among warfarin users was 72. 
The pattern of tumor spreading and tumor histology at diagnosis were similar in all groups. Curative-intent surgery 
was more common among anticoagulant nonusers than users (66.8% and 33.3%, respectively). The distribution of 
each background variable is presented in Table 1. 
Breast cancer survival in relation to pre-diagnostic use of anticoagulants 
When comparing pre-diagnostic users of any anticoagulant to nonusers, there was no significant risk association for 
breast cancer survival (multivariable HR=1.00, 95% CI 0.93-1.07) (Table 2). Short-term use (≤ 1 year) was associated 
with a statistically significant risk decrease in both the age- and multivariable-adjusted analyses. In the analysis 
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comparing pre-diagnostic warfarin users to anticoagulant nonusers, there was no statistically significant risk 
association (overall multivariable HR=0.97, 95% CI 0.89-1.06) (Table 2). When comparing pre-diagnostic LMWH users 
to anticoagulant nonusers, there was a statistically significant risk decrease (multivariable HR=0.71, 95% CI 0.59-
0.85). This risk decrease was limited to short-term LMWH users. Table 2 shows results subdivided by the pre-
diagnostic use of different anticoagulants. Results stratified by the amount and intensity of anticoagulant use are 
presented in Supplementary Table 2. The results were similar to those stratified by duration of use. 
Breast cancer survival in relation to post-diagnostic use of anticoagulants 
When comparing breast cancer survival in post-diagnostic anticoagulant users and nonusers, the risk was 
significantly increased for both current users (HR=1.41, 95% CI 1.33-1.49) and previous users (HR=1.30, 95% CI 1.22-
1.39) (Table 3). With the exception of those using anticoagulants for 4 years or more (multivariable HR=1.06, 95% 
0.96-1.19), the risk associations were similar in the analyses stratified by duration of anticoagulant use. In the lag-
time analysis, the increased risk was attenuated but remained significant in all cases, except among short-term users 
and previous users. 
When comparing warfarin users to anticoagulant nonusers, the risk of breast cancer death was elevated among 
previous users and current users (HR=1.58, 95%CI 1.45-1.72 and HR=1.10, 95% CI 1.02-1.19, respectively) (Table 3). 
However, the risk increase disappeared for previous users in the lag-time analyses. In contrast, the risk of breast 
cancer death remained practically unchanged for current warfarin users. 
When compared to anticoagulant nonusers, current LMWH users were at a significantly higher risk of breast cancer 
death (HR=2.62, 95% CI 2.42-2.83); but previous LMWH use was not associated with any risk increase. The risk 
increase was limited to long-term users (≥ 2 years) (HR=3.39, 95% CI 3.00-3.82). When LMWH use was lagged for 3 
years in the lag-time analysis, the observed risk increases were attenuated and disappeared. The results for post-
diagnostic use of any anticoagulant stratified by use amount and intensity are presented in Supplementary Table 3. 
Subgroup analysis 
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After a Bonferroni correction for multiple testing, age at diagnosis, number of mammography screens, tumor 
spreading at diagnosis, primary breast cancer treatment, antihypertensive use, and indications for anticoagulant use 
all significantly modified the breast cancer mortality associations for anticoagulants in general (Figure 1). The risk 
increase among anticoagulant users was only significant for participants diagnosed with breast cancer at age 62 or 
younger (p value for interaction term <0.001). Having metastatic disease at diagnosis, nonsurgical primary treatment 
(p<0.001 for each), and histology other than ductal or lobular carcinoma (p=0.002) removed the risk association. 
Simultaneous use of antihypertensive drugs and anticoagulants ameliorated the risk increase (p<0.001), except 
among LMWH users; in LMWH users, the risk increase was stronger when antihypertensive drugs had been used 
simultaneously (p=0.002). When patients had not received a mammography screening, there was no elevated risk 
associated with anticoagulant use (p<0.001). Furthermore, the risk of breast cancer death was higher among 
anticoagulant users with a recorded diagnosis of atrial fibrillation (p=0.002). When comparing women who had 
initiated anticoagulant use before breast cancer diagnosis to those who used anticoagulants after diagnosis, the risk 
of breast cancer death was significantly lower among the (p=0.034) (Figure 1). This effect modification was generally 
similar for all anticoagulant subtypes (not shown). 
Sensitivity analysis 
After excluding patients with metastatic disease or unknown spreading at diagnosis, the risk of breast cancer death 
increased slightly among anticoagulant users (multivariable HR=1.67, 95% CI 1.56-1.79) compared to those in the 
main analysis. A similar association was observed for other anticoagulant user categories, except for previous LMWH 
users. However, the effect was attenuated or missing for some categories in the lag-time analyses (Table 4). 
Including the timing of breast cancer diagnosis (year of diagnosis) in the sensitivity analysis of the Cox regression had 
virtually no effect on results (Supplementary Table 4). 
Among 5,412 women with data on ER, PR, and HER2 status, the risk of breast cancer death was elevated among 
anticoagulant users compared to nonusers. The risk was also elevated in LMWH users compared to anticoagulant 
nonusers independent of ER or PR status; however, this elevation was not evident in patients receiving warfarin. On 
the other hand, among women with triple negative disease, anticoagulant use (both overall and for each subtype) 
was associated with a significantly elevated risk of breast cancer death (Supplementary Table 5). 
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We also compared the risk of breast cancer death between warfarin-only and LMWH-only users and found no risk 
association in general (HR=0.94, 95% CI 0.85-1.05). However, when women were stratified by treatment duration, 
those who used these medications for 2 years or less had a 1.3-fold risk of breast cancer death. In contrast, use of 
these medications for 3 years or more was associated with 0.6-fold risk of breast cancer death (not shown). 
In an additional sensitivity analysis, we restricted the cohort to those who underwent curative-intent surgery. In this 
analysis, the risk of breast cancer death was elevated 1.7-fold in anticoagulant users compared to nonusers. The risk 
increase was attenuated in the lag-time analysis (not shown). 
DISCUSSION 
According to the literature, there are several specific pathways that may link the coagulation cascade to breast 
cancer growth and progression (e.g., via angiogenesis, which is vital for tumor cells) [5-10]. Several anticoagulant 
subtypes (i.e., warfarin, direct thrombin inhibitors, and LMWH) are postulated to improve breast cancer survival by 
affecting the growth and spread of tumors [11-16]. Therefore, there has been increasing interest in clarifying the 
association between anticoagulant use and breast cancer survival. In this epidemiological study, we did not observe 
a positive effect of anticoagulant use on survival; this was true when examining anticoagulants in general and by 
subtype. 
To the authors’ knowledge, only one previous observational study [17] has evaluated the association between breast 
cancer survival and anticoagulant use. That study was limited to warfarin users; moreover, though the study 
included a relatively large number of breast cancer cases, its number of warfarin users was low (400). That study 
reported an approximately 1.4-fold increase in breast cancer mortality among warfarin users. While that result is 
similar to those described here, that study did not examine other anticoagulant drugs. Furthermore, that study did 
not evaluate the impact that the timing of anticoagulant use has on the survival of breast cancer patients. 
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Our study revealed that, although post-diagnostic anticoagulant use was associated with an increased risk of breast 
cancer death, using anticoagulants for more than 4 years eliminated that risk. The risk association was particularly 
elevated among women who used LMWH for 2 years or more (3.4-fold risk of breast cancer death). However, the 
increase in risk appeared limited to active LMWH users; it did not persist when LMWH use was terminated. Using 
warfarin for 2 years or less after breast cancer diagnosis was also associated with an increased risk of breast cancer 
death. The risk increase was more significant for previous warfarin use than for current use. In a supplemental 
analysis, the risk of breast cancer death was significantly lower in warfarin users compared to women being treated 
with other anticoagulant drugs. However, this likely reflects the high risk associated with LMWH use. For LMWH, the 
risk increase was most likely attributable to reverse causation by terminal-phase breast cancer because LMWH is the 
drug of choice for all VTE treatment, including VTEs caused by advanced cancer. Because the risk association 
between anticoagulant use and breast cancer death was attenuated or eliminated in lag-time analyses, the 
relationship is not causal. In addition, no risk association was observed between pre-diagnostic anticoagulant use 
and breast cancer death. Furthermore, women initiating anticoagulant therapy after breast cancer diagnosis were at 
a higher risk of dying from breast cancer than those who became anticoagulant users prior to diagnosis. 
In the analysis evaluating the risk associated with pre-diagnostic anticoagulant use, we found that low-dose, short-
term use of LMWH was associated with a reduced risk of breast cancer death. This association is unlikely to be causal 
because no such effect was observed with long-term use. Therefore, our study does not support the theory 
postulated following previous in vivo and in vitro experiments that LMWH use improves survival [15-16]. 
In lag-time analyses evaluating the impact that the timing of anticoagulant use plays, the risk increase observed in 
the main analysis was attenuated but remained elevated. For LMWH users, the timing of anticoagulant use reduced 
the risk of breast cancer death; however, among women who had used LMWH for 2 years or more, the risk of death 
from breast cancer remained nearly double that of nonusers. Risk associations were greatly modified by having an 
indication for anticoagulant use. Unfortunately, however, this finding is less conclusive because data on indications 
for anticoagulant use in primary healthcare settings were not available. The increased risk of breast cancer death 
seems limited to short-term use because thromboembolic events are more common in patients with advanced 
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cancer [1] and are associated with a poorer prognosis [2]. However, thrombosis could be a long-term risk factor 
because the risk increase did not disappear in the lag-time analysis. 
According to our subgroup analysis, the risk of breast cancer death was particularly high for those who had a local or 
locally advanced disease. An elevated risk of breast cancer death was also observed among those diagnosed with 
atrial fibrillation. Because the risk of cancer-induced thrombosis can be assumed to be lowest for those with atrial 
fibrillation, this finding supports the theory that thrombosis promotes cancer progression and worsens patient 
prognosis (rather than the reverse). On the other hand, compared to exclusively post-diagnostic anticoagulant users, 
those individuals who were both pre-diagnostic and post-diagnostic users had a lower risk of breast cancer death. In 
either case, the use of anticoagulants was not associated with an elevated risk of breast cancer death. 
This study has several strengths. The sample includes all breast cancer cases occurring in a nationwide population 
over a period of 19 years (n=73,170), thereby minimizing selection bias. We believe that this is the largest and most 
comprehensive epidemiological study on breast cancer survival in anticoagulant users. Moreover, we had detailed 
information on tumor spread and histology at the time of diagnosis. We also had comprehensive data on 
anticoagulant use, including the timing of anticoagulant use. Furthermore, it was possible to stratify cohort members 
according to anticoagulant subtype, usage amount, duration of use, and intensity of use. The analyses were adjusted 
for multiple background variables to minimize bias. In a subpopulation of our cohort, we were able to evaluate the 
effect that important prognostic factors, such as ER, PR, and HER2 status, have on breast cancer survival. 
This study also had some limitations. We had no information on smoking habits, but smoking has been associated 
with worse breast cancer prognoses [28]. We had no data on hormone replacement therapy or body mass index. 
Similarly, clinicians report only the most severe cases of obesity to health registries; as such, information related to 
obesity was limited. In addition, we did not have data on socioeconomic factors that may influence breast cancer 
survival [29]. We did not have data on anticoagulant use prior to 1995, which limits our ability to evaluate long-term 
risk associations. Moreover, we did not have information on indications for anticoagulant use identified during 
primary healthcare visits; without this data we could not fully evaluate the effect that indications for anticoagulant 
use have on breast cancer survival. Furthermore, our data did not include anticoagulants used during hospital 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 25, 2019; DOI: 10.1158/1055-9965.EPI-19-0147 
14 
inpatient visits; therefore, some exposure misclassification is possible. However, we consider this to be a minor 
concern because indications for anticoagulant use other than thromboprophylaxis would continue after hospital 
discharge; thus, those indications would be captured in our anticoagulant use data. Finally, we did not have data on 
mammography screenings performed outside the national screening program, and this could be a source of healthy 
user bias. 
For clinicians, the primary takeaway of this study is that anticoagulants provide no benefit for cancer control, even 
though they are useful in the treatment of thrombosis. Our study does not find any support for the prophylactic use 
of such potentially dangerous medications. Moreover, because our results suggest that anticoagulant use is 
correlated with cancer death, epidemiologists should adjust for anticoagulant use in future studies. Despite 
promising results from previous in vitro and in vivo studies, bioscience researchers should be aware that the positive 
effects of anticoagulant use on cancer survival are not evident at the population level. 
 Conclusion 
General anticoagulant use, warfarin use, and LMWH use confer no clinical benefits against breast cancer. In fact, the 
risk of breast cancer death is increased for post-diagnostic anticoagulant users. Among pre-diagnostic users, the low-
dose, short-term use of LMWH is associated with improved survival; however, other patterns of LMWH use predict a 
risk of death similar to that of nonusers. It is possible that the association between thrombosis and cancer masks 
some potential survival benefit. Future studies should focus on determining whether the administration of newer 
oral anticoagulants is associated with breast cancer survival; direct thrombin inhibitors, such as dabigatran, have 
been reported to reduce breast cancer metastasis [7-9]. 
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Table 1   Population characteristis of the study population stratified by 
anticoagulant usage during 1995-2015. 
Anticoagulant usage 
Type of anticoagulant 
No Yes 
Warfarin users* LMWH users* 
n of women in the study population 47,548 25,622 10,594 14,224 
Median year of breast cancer diagnosis 2005 2006 2004 2007 
Breast cancer deaths 8,085  (17.0%) 2,815 (11.0%) 1,404 (13.3%) 1,312 (9.2%) 
All deaths 14,418 (30.3%) 8,102 (31.6%) 4,531 (42.3%) 2,961 (20.8%) 
Median age at diagnosis (years) 59 66 72 62 
Median follow-up after breast cancer diagnosis 
(years) 
5.7 6.0 6.3 5.5 
Median follow-up from diagnosis to breast cancer 
death (years) 
2.9 3.8 3.5 4.7 
Age at diagnosis in 2 groups 
≤62 years 
28,546 (60.0%) 
10,359 
(40.4%) 
2,628 (24.8%) 7,605 (53.5%) 
>62 years 
19,002 (40.0%) 
15,263 
(59.6%) 
7,966 (75.2%) 6,619 (46.5%) 
Tumor spreading at diagnosis 
Localized 
23,782 (50.0%) 
12,854 
(50.2%) 
5,326 (50.3%) 6,943 (48.8%) 
Locally advanced 15,569 (32.7%) 8,474 (33.1%) 3,407 (32.2%) 5,040 (35.4%) 
Metastatic 4,071 (8.6%) 2,054 (8.2%) 855 (8.1%) 1,182 (8.3%) 
Unknown 4,126 (8.7%) 2,240 (8.7%) 1,006 (9.5%) 1,059 (7.4%) 
Tumor histology 
Invasive ductal 
35,930 (75.6%) 
19,118 
(74.6%) 
7,800 (73.6%) 10,700 (75.2%) 
Invasive lobular 7,785 (16.4%) 4,461 (17.4%) 1,805 (17.0%) 2,581 (18.1%) 
Other invasive 3,801 (8.0%) 2,013 (7.9%) 980 (9.3%) 923 (6.5%) 
Unknown 32 (0.06%) 30 (0.1%) 9 (0.08%) 20 (0.1%) 
Primary therapy 
Curative-intent surgery 31,748 (66.8%) 8,539 (33.3%) 6,939 (65.5%) 9,630 (67.7%) 
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Other/unknown 
15,800 (33.2%) 
17,083 
(66.7%) 
3,655 (34.5%) 4,594 (32.2%) 
Charlson co-morbidity score (points) 
0 
37,173 (78.2%) 
17,221 
(67.2%) 
6,917 (65.3%) 9,299 (65.4%) 
1 1,783 (3.7%) 1,756 (6.9%) 746 (7.0%) 948 (6.7%) 
2 or more 8,592 (18.1%) 6,645 (25.9%) 2,931 (27.7%) 3,977 (28.0%) 
Mammography screening participation (n) 
0 
18,595 (39.1%) 
12,185 
(47.6%) 
6,216 (58.7%) 5,357 (37.7%) 
1-3 14,225 (29.9%) 7,021 (27.4%) 2,551 (24.1%) 4,432 (31.2%) 
4 or more 14,728 (31.0%) 6,416 (25.0%) 1,827 (17.2%) 4,425 (31.1%) 
Obesity** 
Yes 193 (0.4%) 234 (0.9%) 102 (1.0%) 154 (1.1%) 
No 
47,355 (99.6%) 
25,388 
(99.1%) 
10,492 (99.0%) 14,070 (98.9%) 
Diabetes 
Yes 
41,345 (87.0%) 
20,149 
(78.6%) 
2,751 (26.0%) 2,566 (18.0%) 
No 6,203 (12.7%) 5,473 (21.4%) 7,843 (74.0%) 11,658 (82.0%) 
Use of other medication 
Anti-hypertensive drug 
users 
29,533 (62.1%) 
21,336 
(83.3%) 
9,981 (94.2%) 10,812 (76.0%) 
Statin users 
13,460 (28.3%) 
11,986 
(46.8%) 
5,269 (49.7%) 5,993 (42.1%) 
Hormonal therapy 18,682 (39.3%) 8,982 (35.1%) 3,157 (30.0%) 5,552 (39.0%) 
Recorded diagnoses of: 
Atrial fibrillation 207 (0.4%) 2,011 (7.8%) 1,886 (17.8%) 802 (5.6%) 
Pulmonary embolism 22 (0.05%) 274 (1.1%) 190 (1.8%) 204 (1.4%) 
Venous 
thromboembolism 
13 (0.03%) 74 (0.3%) 52 (0.5%) 63 (0.4%) 
* = Anticoagulant user status not mutually exclusive, LMWH = low-molecular
weight heparin 
**=Obesity is based on diagnosis obtained from HILMO as reported by clinicians, exact definition 
cannot be given. 
 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 25, 2019; DOI: 10.1158/1055-9965.EPI-19-0147 
20 
Table 2 Pre-diagnostic use  of 1) anticoagulants overall, 2) warfarin compared to anticoagulant non-
users, 3) low-molecular weight heparin (LMWH) compared to anticoagulant non-users and  
stratified by duration of usage.  Age-adjusted and multivariable-adjusted hazard ratios (95% CI) 
related to all breast cancer deaths. Statistically significant results are bolded. 
n of 
deaths 
Age-adjusted 
Multivariable-
adjusted 
Anticoagulants compared to non-users 
None 9,940 Ref Ref 
Any 960 0.94 (0.87-1.00) 1.00 (0.93-1.07) 
Duration of anticoagulant use 
≤1 year 321 0.76 (0.68-0.85) 0.85 (0.76-0.95) 
2-3 years 269 1.04 (0.92-1.18) 1.11 (0.98-1.26) 
4 or more years 370 1.09 (0.98-1.21) 1.09 (0.98-1.21) 
Warfarin compared to anticoagulant non-users** 
Non-user 9,940 Ref Ref 
Any 579 0.93 (0.85-1.01) 0.97 (0.89-1.06) 
Duration of warfarin 
use 
≤1 year 190 0.84 (0.73-0.97) 0.89 (0.77-1.03) 
2-4 years 211 0.98 (0.85-1.12) 1.01 (0.88-1.16) 
5 or more years 178 0.97 (0.84-1.13) 1.02 (0.88-1.19) 
LMWH compared to anticoagulant non-users** 
Non-user 9,940 Ref Ref 
Any 127 0.62 (0.52-0.74) 0.71 (0.59-0.85) 
Duration of LMWH use 
≤1 year 105 0.59 (0.48-0.71) 0.69 (0.57-0.83) 
2 or more  years 22 0.80 (0.53-1.22) 0.84 (0.55-1.27) 
* Adjusted variables are: age, stage of disease at diagnosis, BrCa treatment, Charlson Score, obesity, participation
in mammography screening, diabetes, use of antihypertensive drugs, use of statins, hormonal therapy, tumor 
histology, atrial fibrillation, venous thromboembolism, pulmonary embolism. 
**=Use of warfarin/LMWH with or without use of other 
anticoagulants 
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Table 
3 
Post-diagnostic use of 1) anticoagulants overall, 2) Warfarin compared to anticoagulant non-users,  3) low-
molecular weight heparin (LMWH) compared to anticoagulant non-users. Stratified by  duration of usage. 
Multivariable-adjusted and lag-time hazard ratios (95% CI) related to all breast cancer deaths. Statistically 
significant results are bolded. 
Multivariabl
e-adjusted* 
n of 
deaths 
1-year lag-
time 
2-year lag-
time 
3-year lag-
time 
Anticoagulants compared to non-users 
None 8,085 Ref Ref Ref Ref 
current 
1,323 
1.41 (1.33-
1.49) 
1.29 (1.21-
1.36) 
1.13 (1.06-
1.20) 
1.10 (1.03-
1.18) 
previous 
1,492 
1.30 (1.22-
1.39) 
1.05 (0.97-
1.14) 
0.97 (0.88-
1.08) 
0.97 (0.87-
1.10) 
Duration of anticoagulant use 
≤1 year 
1,217 
1.40 (1.32-
1.49) 
1.26 (1.17-
1.35) 
1.03 (0.95-
1.12) 
1.00 (0.92-
1.09) 
2-3 years 
796 
1.54 (1.42-
1.67) 
1.27 (1.16-
1.39) 
1.27 (1.15-
1.40) 
1.25 (1.13-
1.39) 
4 or more years 
802 
1.06 (0.96-
1.19) 
1.21 (1.10-
1.34) 
1.15 (1.04-
1.28) 
1.16 (1.04-
1.28) 
Warfarin compared to anticoagulant non-
users** 
Non-user 8,085 Ref Ref Ref Ref 
current 
589 
1.10 (1.02-
1.19) 
1.22 (1.13-
1.31) 
1.12 (1.04-
1.22) 
1.13 (1.04-
1.22) 
previous 
815 
1.58 (1.45-
1.72) 
1.15 (1.02-
1.29) 
1.08 (0.94-
1.24) 
1.02 (0.87-
1.21) 
Duration of warfarin 
use 
≤2 year 
758 
1.32 (1.23-
1.43) 
1.17 (1.08-
1.28) 
1.01 (0.92-
1.11) 
1.03 (0.92-
1.14) 
3-6 years 
383 
1.01 (0.89-
1.14) 
1.17 (1.04-
1.32) 
1.13 (1.00-
1.28) 
1.11 (0.98-
1.26) 
7 or more years 
263 
0.91 (0.72-
1.15) 
1.14 (0.96-
1.37) 
1.14 (0.97-
1.35) 
1.11 (0.94-
1.30) 
LMWH compared to anticoagulant non-
users** 
Non-user 8,085 Ref Ref Ref Ref 
current 
643 
2.62 (2.42-
2.83) 
1.74 (1.57-
1.93) 
1.30 (1.15-
1.46) 
1.11 (0.96-
1.27) 
previous 
669 
0.99 (0.90-
1.09) 
1.00 (0.89-
1.11) 
0.90 (0.78-
1.03) 
0.85 (0.71-
1.01) 
Duration of LMWH 
use 
≤1 year 
911 
1.40 (1.31-
1.51) 
1.16 (1.06-
1.27) 
0.95 (0.85-
1.06) 
0.89 (0.79-
1.01) 
2 or more years 
401 
3.39 (3.00-
3.82) 
2.28 (1.92-
2.70) 
2.01 (1.63-
2.49) 
1.74 (1.35-
2.24) 
* Adjusted variables are: age, stage of disease at diagnosis, BrCa treatment, Charlson Score, obesity, participation in
mammography screening, diabetes, use of antihypertensive drugs, use of statins, hormonal therapy, tumor histology, atrial 
fibrillation, venous thromboembolism, pulmonary embolism. 
**=Use of warfarin/LMWH with or without use of 
other anticoagulants 
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Table 4 Sensitivity analysis where metastatic and unknown disease at diagnosis have been excluded, leaving 60,679 women. Analyzed by post-diagnostic use of 1) 
anticoagulants overall, 2) Warfarin compared to anticoagulant non-users,  3) low-molecular weight heparin (LMWH) compared to anticaoagulant non-users and 4) 
warfarin compared to non-warfarin anticoagulant users.  Age-adjusted, multivariable-adjusted and lag-time hazard ratios (95% CI) related to all breast cancer 
deaths. Statistically significant results are bolded. 
Multivariable-
adjusted* n of deaths Age-adjusted 1-year lag-time 2-year lag-time 3-year lag-time 
Anticoagulants compared to non-users 
None 5,084 Ref Ref Ref Ref Ref 
current 860 1.90 (1.78-2.03) 1.67 (1.56-1.79) 1.46 (1.35-1.57) 1.21 (1.11-1.31) 1.19 (1.09-1.29) 
previous 960 1.51 (1.39-1.64) 1.35 (1.24-1.47) 1.08 (0.98-1.19) 1.02 (0.91-1.15) 1.01 (0.89-1.16) 
Warfarin compared to anticoagulant non-users** 
Non-user 5,084 Ref Ref Ref Ref Ref 
current 384 1.16 (1.05-1.27) 1.22 (1.11-1.34) 1.30 (1.19-1.44) 1.13 (1.01-1.25) 1.16 (1.04-1.28) 
previous 520 1.65 (1.48-1.84) 1.65 (1.48-1.84) 1.20 (1.04-1.38) 1.15 (0.99-1.35) 1.06 (0.87-1.28) 
LMWH compared to anticoagulant non-users** 
Non-user 5,084 Ref Ref Ref Ref Ref 
current 427 3.32 (3.01-3.65) 3.16 (2.87-3.48) 2.11 (1.86-2.38) 1.44 (1.23-1.68) 1.19 (1.00-1.42) 
previous 453 0.95 (0.84-1.06) 1.01 (0.90-1.13) 0.92 (0.81-1.06) 0.86 (0.73-1.01) 0.82 (0.67-1.00) 
Warfarin compared to other anticoagulants 
Other anticoagulants 906 Ref Ref Ref Ref Ref 
Warfarin users 914 0.95 (0.86-1.05) 0.88 (0.80-0.98) 1.16 (1.04-1.30) 1.11 (0.98-1.26) 1.18 (1.04-1.35) 
* Adjusted variables are: age, stage of disease at diagnosis, BrCa treatment, Charlson Score, obesity, participation in mammography screening, diabetes, use of
antihypertensive drugs, use of statins, hormonal therapy, tumor histology, atrial fibrillation, venous thromboembolism, pulmonary embolism. 
**=Use of warfarin/LMWH with or without use of other 
anticoagulants 
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Figure Legends 
Figure 1 - Subgroup analysis between anticoagulant users and non-users for breast cancer death in post-
diagnostic setting. P for interaction is given under the variable if an effect modification was considered 
possible. Statistically significant P values are bolded. 
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